Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) posted its earnings results on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03), FiscalAI reports.
Oncolytics Biotech Trading Down 0.5%
NASDAQ:ONCY traded down $0.00 during mid-day trading on Friday, hitting $0.37. The company had a trading volume of 1,263,696 shares, compared to its average volume of 979,165. The business has a fifty day simple moving average of $0.58 and a 200-day simple moving average of $0.83. Oncolytics Biotech has a 1 year low of $0.34 and a 1 year high of $1.30. The firm has a market capitalization of $48.51 million, a price-to-earnings ratio of -1.09 and a beta of 1.26.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on ONCY shares. Weiss Ratings raised shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. HC Wainwright dropped their price objective on shares of Oncolytics Biotech to $5.00 and set a “buy” rating for the company in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Oncolytics Biotech presently has a consensus rating of “Hold” and an average price target of $5.00.
About Oncolytics Biotech
Oncolytics Biotech is a clinical-stage biotechnology company developing cancer immunotherapies. Its lead product candidate, pelareorep, is an investigational virus-based therapy intended to activate the immune system against cancer. The company is studying pelareorep in combination with other treatments, including chemotherapy and immunotherapies, for cancers such as breast cancer and pancreatic cancer. Pelareorep is not an approved treatment. Based in Canada, Oncolytics conducts clinical development through research and trials involving patients and collaborators in multiple regions.
Read More
- Five stocks we like better than Oncolytics Biotech
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
